Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Other Non-Current Liabilities (2018 - 2025)

Plus Therapeutics (PSTV) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $25.1 million as the latest value for Q1 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $25.1 million in Q1 2025 year-over-year; TTM through Mar 2025 was $25.1 million, a N/A change, with the full-year FY2020 number at $7000.0, down 99.9% from a year prior.
  • Other Non-Current Liabilities was $25.1 million for Q1 2025 at Plus Therapeutics, up from $3000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $25.1 million in Q1 2025 to a low of $3000.0 in Q3 2021.